Firm
The tie-up between Perkins Coie and Ashurst may generate some striking numbers, but independent IP firms need not worry yet, according to practitioners
Perkins Coie’s US patent prosecution strength could provide Ashurst with an opportunity to enter an untapped market in Australia, but it may not be easy
Mitesh Patel at Reed Smith outlines why the US Copyright Office and courts have so far dismissed AI authorship and how inventors can protect AI-generated works
Xia Zheng, founder of AFD China, discusses balancing legal work with BD, new approaches to complex challenges, and the dangers of ‘over-optimism’
Sponsored
Sponsored
-
Sponsored by Januar Jahja & PartnersDespite the widespread social, health, and economic devastation caused by COVID-19, it has largely been business as usual at the Indonesian IP Office (DGIP) since the start of the pandemic. While there certainly have been some minor disruptions and corresponding adjustments, overall the impact so far appears to have been minimal.
-
Sponsored by Griffith HackIn early 2019, IP Australia initiated a comprehensive research phase exploring Australia’s design ecosystem, including voices from the industry, design forums, economic analysis and business surveys. Following this 12-month exercise, the regulator has proposed the following changes:
-
Sponsored by Hanol IP & LawRecently, the Korean Patent Court rendered a favourable decision on the patentability of medical use inventions in which strict scrutiny was employed for two aspects of the enablement and inventiveness requirements.
-
Sponsored by Smart & BiggarKwan Loh and Jamie-Lynn Kraft of Smart & Biggar review the changes made to Canadian trademark law and offer tips on how to navigate the road ahead
-
Sponsored by Maiwald Intellectual PropertyIn the present case, the German Federal Court of Justice again had to deal with the question of how a representation of information within the meaning of Article 52(2)(d) EPC is to be distinguished from a technical feature.
-
Sponsored by InspicosThe Enlarged Board of Appeal of the EPO (EBA) has recently issued opinion G 3/19, which concludes that plants and animals exclusively obtained by “essentially biological processes” are exempt from patentability. This finding only affects patents derived from patent applications filed after July 1 2017.